Experimental Vaccine Reduces Risks Of HIV/AIDS Contagion

Thai health authorities have presented yesterday in Bangkok the results of an HIV/AIDS vaccine studey conducted on more than 16,000 people.

The study conducted in Thailand was sponsored by the US Army Medical Research and the National Institute of Health.

The experimental vaccine (known as RV144) is a combination of two genetically engineered vaccines developed by Sanofi-Aventis SA and VaxGen Inc., whih had failed in previous trials.

The protection offered by this new vaccine is very low, as it only reduces the risk of contagion by 31.2 percent, but the results give some indication that researchers are heading in the right direction.

The question now is whether this vaccine could be equally effective against other strains of the virus in other parts of the world, as the RV144 vaccine is highly specific to the strains found in Thailand.

The AIDS virus has infected 33 million people and killed 25 million worldwide since it was identified in the eighties.

Cocktails of drugs can keep the virus under control but there is currently no cure.

More information on

  • The New York Times
  • For First Time, AIDS Vaccine Shows Some Success in Trials

  • Bloomberg.com
  • HIV Vaccine Study May Lift Hopes After Merck, Sanofi Setbacks

About the Author

admin

Leave a Reply

You must be logged in to post a comment.